Clinical trial • Phase I • Neurology
ACI-19764 for Healthy volunteers
Phase I trial of ACI-19764 for Healthy volunteers. Randomised, placebo (dose and schedule not specified)-controlled. 78 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Healthy volunteers
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 17-11-2025
- First CTIS Authorization Date
- 13-01-2026
Trial design
Randomised, placebo (dose and schedule not specified)-controlled Phase I trial across 1 site in Netherlands.
- Randomised
- Yes
- Comparator
- Placebo (dose and schedule not specified)
- Single Multiple Or Escalation Dose Combined
- Yes
- Target Sample Size
- 78
- Trial Duration For Participant
- 212
Eligibility
Recruits 78 Vulnerable population selected; no details provided on consent or assent handling..
- Vulnerable Population
- Vulnerable population selected; no details provided on consent or assent handling.
Recruitment
- Planned Sample Size
- 78
- Recruitment Window Months
- 7
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 78
Netherlands
- Earliest CTIS Part Ii Submission Date
- 09-01-2026
- Latest Decision Or Authorization Date
- 13-01-2026
- Processing Time Days
- 4
- Number Of Sites
- 1
- Number Of Participants
- 78
Sites
- Site Name
- Pharmaceutical Research Associates Group B.V.
- Department Name
- Program Management
- Contact Person Name
- Renger Tiessen
- Contact Person Email
- Renger.Tiessen@iconplc.com
- Number Of Participants
- 78
Sponsor
Primary sponsor
- Full Name
- AC Immune S.A.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Switzerland
Investigational products
- Investigational Product Name
- ACI-19764
Related trials
Other published trials that may interest you.